As company refocuses, Perrigo names new CEO

10 October 2018

Ireland-headquartered generic and OTC drugmaker Perrigo (NYSE: PRGO), which recently said it was restructuring into two separate units, has announced the appointment of Murray Kessler as president, chief executive and member of the board of directors, effective immediately.

Perrigo said that Uwe Roehrhoff has stepped down as president, CEO and board member and will make himself available to ensure a smooth and successful transition.

Perrigo has seen a number of changes in its leadership, since Joe Papa resigned as chief executive in April 2016, and his successor, John Hendrickson quit the post in June 2017. Mr Roehrhoff took over as CEO on January this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK